Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

ATLANTA, April 11, 2025 /PRNewswire/ -- On April 01, 2025, OrderlyMeds received a Cease-and-Desist letter from Eli Lilly regarding the compounding of Tirzepatide. This is our open response.